| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
131-204 |
DRI_Background |
denotes |
Bone is the primary site of skeletal metastasis in prostate cancer (PCa). |
| T2 |
205-341 |
DRI_Background |
denotes |
Atelocollagen (ATE)-mediated siRNA delivery system can be used to silence endogenous genes involved in PCa metastatic tumor cell growth. |
| T3 |
342-476 |
DRI_Outcome |
denotes |
However, we hope that the delivery system can target PCa cells to reduce damage to the bone tissue and improve the therapeutic effect. |
| T4 |
477-604 |
DRI_Background |
denotes |
RNA aptamer (APT) A10-3.2 has been used as a ligand to target PCa cells that express prostate-specific membrane antigen (PSMA). |
| T5 |
605-752 |
DRI_Background |
denotes |
APT was investigated as a PSMA-targeting ligand in the design of an ATE-based microRNA (miRNA; miR-15a and miR-16-1) vector to PCa bone metastasis. |
| T6 |
753-940 |
DRI_Background |
denotes |
To observe the targeted delivery and transfection efficiency of ATE-APT in PSMA-overexpressing cells, luciferase activity and biodistribution of nanoparticles in Balb/c mice was analyzed. |
| T7 |
941-1070 |
DRI_Background |
denotes |
The anticancer effect of nanoparticles in vivo was investigated using the survival times of human PCa bone metastasis mice model. |
| T8 |
1071-1280 |
DRI_Outcome |
denotes |
Luciferase assays of pGL-3 expression against PC3 (PSMA(-)) and LNCaP (PSMA(+)) cells showed that the transfection efficiency of the synthesized DNA/ATE-APT complex was higher than that of the DNA/ATE complex. |
| T9 |
1281-1372 |
DRI_Outcome |
denotes |
The anticancer efficacy of miRNA/ATE-APT was superior to those of other treatments in vivo. |
| T10 |
1373-1520 |
DRI_Outcome |
denotes |
This PSMA-targeted system may prove useful in widening the therapeutic window and allow for selective killing of PCa cells in bone metastatic foci. |
